{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:17:57Z","timestamp":1787894277325,"version":"build-2784847793"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Carbapenem-resistant\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (CRKP) causes severe high-mortality nosocomial pneumonia. Ceftazidime-avibactam (CAZ-AVI) and tigecycline (TGC) are key CRKP antimicrobials, but direct comparative efficacy and safety data are limited. This retrospective study compared clinical efficacy and safety of CAZ-AVI-based versus TGC-based regimens for CRKP pneumonia, and explored factors associated with all-cause mortality to inform clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 63 patients with CRKP pulmonary infection admitted to Shaanxi Provincial People's Hospital from January 2023 to May 2025 were retrospectively enrolled. Patients were divided into the CAZ-AVI-based regimen group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200933) and the TGC-based regimen group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930) according to their treatment regimen. Differences in therapeutic efficacy, microbiological clearance, and adverse events between the two groups were compared, and logistic regression analysis was performed to explore factors associated with all-cause mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No statistically significant differences in baseline clinical characteristics were observed between groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). Bacterial clearance rate was significantly higher in the CAZ-AVI than TGC group (72.73% vs. 36.67%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004). No statistically significant differences were seen in clinical response, 28-day mortality, overall in-hospital mortality, superinfection, or hepatic and renal adverse events (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). However, coagulation abnormalities (70.00% vs. 27.27%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) and thrombocytopenia (43.33% vs. 15.15%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.013) were significantly higher in the TGC than CAZ-AVI group. Firth penalized multivariable logistic regression identified exploratory associations of advanced age (adjusted OR\u2009=\u20091.12, 95% CI 1.03\u20131.22,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.011) and comorbid diabetes mellitus (adjusted OR\u2009=\u20096.24, 95% CI 1.23\u201331.57,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.027) with increased all-cause mortality. These preliminary findings warrant caution; treatment regimen showed no significant association with all-cause mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this exploratory retrospective cohort, CAZ-AVI-based regimens were associated with a higher bacterial clearance rate and a lower incidence of coagulation and platelet abnormalities, while no statistically significant differences were observed in clinical efficacy or survival outcomes between the two regimens. Advanced age and comorbid diabetes mellitus showed exploratory associations with increased all-cause mortality, which warrant attention in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1879917","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:31:10Z","timestamp":1787891470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of ceftazidime-avibactam versus tigecycline in the treatment of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae"],"prefix":"10.3389","volume":"13","author":[{"given":"Tongfei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shaanxi Provincial People\u2019s Hospital","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shaanxi Provincial People\u2019s Hospital","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shaanxi Provincial People\u2019s Hospital","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianpeng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shaanxi Provincial People\u2019s Hospital","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"127249","DOI":"10.1016\/j.micres.2022.127249","article-title":"Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy","volume":"266","author":"Ma","year":"2023","journal-title":"Microbiol Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1582851","DOI":"10.3389\/fmicb.2025.1582851","article-title":"Epidemiology and resistance mechanisms of tigecycline- and carbapenem-resistant Enterobacteriaceae in China: a multicentre genome-based study","volume":"16","author":"Yan","year":"2025","journal-title":"Front Microbiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.2147\/IDR.S431085","article-title":"Risk factors and mortality of elderly patients with hospital-acquired pneumonia of carbapenem-resistant Klebsiella pneumoniae infection","volume":"16","author":"Zhou","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B4","doi-asserted-by":"publisher","first-page":"832655","DOI":"10.3389\/fmed.2022.832655","article-title":"The value of neutrophil-to-lymphocyte ratio for evaluating blood stream infection caused by carbapenem-resistant Klebsiella pneumoniae: a retrospective cohort study","volume":"9","author":"Wu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.2147\/IDR.S475679","article-title":"Ceftazidime-avibactam for the treatment of carbapenem-resistant Klebsiella Pneumoniae infection: a retrospective, single center study","volume":"17","author":"Yu","year":"2024","journal-title":"Infect Drug Resist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/17460913.2026.2675855","article-title":"Genomic impact of prophages on carbapenem-resistant Klebsiella pneumoniae: distribution and functional gene profiles","volume":"21","author":"Ayas","year":"2026","journal-title":"Future Microbiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1442062","DOI":"10.3389\/fcimb.2024.1442062","article-title":"Evaluation of phage-based decontamination in respiratory intensive care unit environments using ddPCR and 16S rRNA targeted sequencing techniques","volume":"14","author":"Shi","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1775450","DOI":"10.3389\/fimmu.2026.1775450","article-title":"Variable progressive behavior of Klebsiella pneumoniae at different sites of infection","volume":"17","author":"Ahmad","year":"2026","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/14787210.2021.1859369","article-title":"New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from gram-negatives","volume":"19","author":"Karvouniaris","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s15010-021-01735-1","article-title":"Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates","volume":"50","author":"Maraki","year":"2022","journal-title":"Infection"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0147323","DOI":"10.1128\/spectrum.01473-23","article-title":"In vitro activity of ceftazidime-avibactam and comparators against OXA-48-like enterobacterales collected between 2016 and 2020","volume":"12","author":"Stone","year":"2024","journal-title":"Microbiol Spectr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"B13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/antibiotics14100994","article-title":"Significant prevalence of dual KPC\/NDM carbapenemase-producing Klebsiella pneumoniae in an ICU cohort in Thessaloniki (2023), including an ST512 isolate co-harboring bla(NDM-1) and bla(KPC-3)","volume":"14","author":"Chatzidimitriou","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.2147\/IDR.S369368","article-title":"Ceftazidime-avibactam as salvage therapy in pediatric liver transplantation patients with infections caused by carbapenem-resistant enterobacterales","volume":"15","author":"Wang","year":"2022","journal-title":"Infect Drug Resist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1345935","DOI":"10.3389\/fcimb.2024.1345935","article-title":"Clinical distribution of carbapenem genotypes and resistance to ceftazidime-avibactam in Enterobacteriaceae bacteria","volume":"14","author":"Zhu","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s40121-021-00542-3","article-title":"Ceftazidime-avibactam-based versus tigecycline-based regimen for the treatment of carbapenem-resistant Klebsiella pneumoniae-induced pneumonia in critically ill patients","volume":"10","author":"Shi","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"106633","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant gram-negative bacterial infections","volume":"60","author":"Kanj","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"106090","DOI":"10.1016\/j.micpath.2023.106090","article-title":"Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis","volume":"179","author":"Karampatakis","year":"2023","journal-title":"Microb Pathog"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s40121-022-00682-0","article-title":"Ceftazidime\/avibactam-based versus polymyxin B-based therapeutic regimens for the treatment of carbapenem-resistant Klebsiella pneumoniae infection in critically ill patients: a retrospective cohort study","volume":"11","author":"Zheng","year":"2022","journal-title":"Infect Dis Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s40121-023-00852-8","article-title":"Combination therapy of ceftazidime\/avibactam for the treatment of patients infected with carbapenem-resistant Klebsiella pneumoniae: a multicenter retrospective study","volume":"12","author":"Lin","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B23","year":"2023"},{"key":"B24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jgar.2020.10.023","article-title":"Clinical characteristics and outcomes of patients with multidrug-resistant gram-negative bacterial infections treated with ceftazidime\/avibactam","volume":"23","author":"Kuang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1097\/MJT.0b013e3182a32df3","article-title":"Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam","volume":"23","author":"Zalts","year":"2016","journal-title":"Am J Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1515\/dx-2020-0057","article-title":"Biochemical biomarkers alterations in coronavirus disease 2019 (COVID-19)","volume":"7","author":"Ciaccio","year":"2020","journal-title":"Diagnosis (Berl)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.3390\/ijms25105061","article-title":"Ngal in the development of acute kidney injury in a murine model of remote ischaemic preconditioning and liver ischaemia reperfusion","volume":"25","author":"Platt","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.hoc.2021.07.002","article-title":"Laboratory methods in the assessment of hereditary hemostatic disorders","volume":"35","author":"Cheves","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"B29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijid.2021.10.028","article-title":"Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient","volume":"113","author":"Gaibani","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2615753","DOI":"10.1155\/2022\/2615753","article-title":"Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in northern China","volume":"2022","author":"Wang","year":"2022","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jgar.2022.01.029","article-title":"Epidemiology and genotypic characteristics of carbapenem resistant enterobacterales in Henan, China: a multicentre study","volume":"29","author":"Jing","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"B32","doi-asserted-by":"publisher","first-page":"116235","DOI":"10.1016\/j.diagmicrobio.2024.116235","article-title":"In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019\u20132021","volume":"109","author":"Lemos-Luengas","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jgar.2020.08.024","article-title":"Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: a systematic review and meta-analysis","volume":"23","author":"Hou","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"B34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3760\/cma.j.issn.0253-2727.2021.07.006","article-title":"[Clinical characteristics and prognostic risk factors analysis of carbapenem-resistant organism in the department of hematology]","volume":"42","author":"Chen","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","article-title":"Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012\u20132016)","volume":"9","author":"Zhang","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.3760\/cma.j.cn112137-20200430-01389","article-title":"[Analysis of pathogen spectrum and antimicrobial resistance of pathogens associated with hospital-acquired infections collected from 11 teaching hospitals in 2018]","volume":"100","author":"Li","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5414\/CP203903","article-title":"Analysis based on Monte Carlo simulation: how effective is tigecycline in routine antimicrobial therapy?","volume":"59","author":"Jin","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"772372","DOI":"10.3389\/fmed.2022.772372","article-title":"Polymyxin B\/tigecycline combination vs. polymyxin B or tigecycline alone for the treatment of hospital-acquired pneumonia caused by carbapenem-resistant Enterobacteriaceae or carbapenem-resistant Acinetobacter baumannii","volume":"9","author":"Chang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jgar.2025.10.007","article-title":"In vitro antibacterial activity of nordihydroguaiaretic acid combined with ceftriaxone against carbapenem-resistant Klebsiella pneumoniae","volume":"46","author":"Luo","year":"2026","journal-title":"J Glob Antimicrob Resist"},{"key":"B40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s15010-023-02108-6","article-title":"Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","volume":"52","author":"Chen","year":"2024","journal-title":"Infection"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s40121-022-00624-w","article-title":"Risk factors for mortality among critical acute pancreatitis patients with carbapenem-resistant organism infections and drug resistance of causative pathogens","volume":"11","author":"Wu","year":"2022","journal-title":"Infect Dis Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/jcm9010275","article-title":"Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia","volume":"9","author":"Jean","year":"2020","journal-title":"J Clin Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"ofaa278","DOI":"10.1093\/ofid\/ofaa278","article-title":"Minimizing time to optimal antimicrobial therapy for Enterobacteriaceae bloodstream infections: a retrospective, hypothetical application of predictive scoring tools vs rapid diagnostics tests","volume":"7","author":"Cwengros","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1879917\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:31:19Z","timestamp":1787891479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1879917\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":44,"alternative-id":["10.3389\/fmed.2026.1879917"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1879917","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1879917"}}